TELA Bio (TELA) Capital Expenditures (QoQ) (2019 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | TELA Bio | 13.26 Mn | -26.28 Mn | 12.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -72.52% |
| Dec 31, 2025 | 430.53% |
| Sep 30, 2025 | -214.91% |
| Jun 30, 2025 | 256.25% |
| Mar 31, 2025 | -87.88% |
| Dec 31, 2024 | -60.60% |
| Sep 30, 2024 | 653.72% |
| Jun 30, 2024 | -168.75% |
| Mar 31, 2024 | -14.15% |
| Dec 31, 2023 | -42.58% |
| Sep 30, 2023 | 640.91% |
| Jun 30, 2023 | -157.39% |
| Mar 31, 2023 | -86.69% |
| Dec 31, 2022 | 726.09% |
| Sep 30, 2022 | 27.37% |
| Jun 30, 2022 | -156.55% |
| Mar 31, 2022 | -36.60% |
| Dec 31, 2021 | 960.00% |
| Sep 30, 2021 | 100.00% |
| Jun 30, 2021 | 13.64% |
| Mar 31, 2021 | 117.46% |
| Dec 31, 2020 | -481.82% |
| Sep 30, 2020 | 17.86% |
| Jun 30, 2020 | -58.82% |
| Mar 31, 2020 | 106.06% |
| Dec 31, 2019 | -56.00% |
| Sep 30, 2019 | 82.93% |
| Jun 30, 2019 | -14.58% |
| Mar 31, 2019 | 140.00% |